Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Kraemer, Susanne ^a   Minarzyk, Anette ^a   Eppendorfer, Steffen ^a   Henneges, Carsten ^a   Hundemer, Hans Peter ^a   Wilhelm, Stefan ^a   Grunze, Heinz ^b  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; Medication regimen; Out patient setting; Relapse; Retention

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM; MOOD STABILIZER; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; INTERVENTION STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGED; CLINICAL TRIAL; DRUG COMBINATION; GERMANY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; LITHIUM; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880184586     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-193     Document Type: Article

References (23)

1. World Health Organisation (WHO) World Health Report 2001: Mental Health: New understanding, new hope 2001, Available at: http://www.who.int/whr/2001/en/annex3_en.pdf. Accessed August 29, 2012, World Health Organisation (WHO).
2. Runge C, Grunze H. Jährliche Krankheitskosten bipolarer Störungen in Deutschland. Nervenarzt 2004, 75:896-903.
3. Grunze H, Dargel S. Acute and long-term treatment for bipolar disorder. Nervenarzt 2010, 81:539-548. 10.1007/s00115-009-2851-9, 20386876.
4. Greenhouse WJ, Meyer B, Johnson SL. Coping and medication adherence in bipolar disorder. J Affect Disord 2000, 59:237-241. 10.1016/S0165-0327(99)00152-4, 10854641.
5. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes towards lithium: relationship to compliance. Arch Gen Psychiatry 1979, 36:866-869. 10.1001/archpsyc.1979.01780080040011, 454105.
6. Grunze H, Vieta E, Goodwin GM, et al. The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010, 11:81-109. 10.3109/15622970903555881, 20148751.
7. Keck PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998, 155:646-652.
8. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK, Valproate V. Lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011, 199:57-63. 10.1192/bjp.bp.110.084822, 21593515.
9. Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorders. J Psychopharmacol 2012, 26(5):644-65223. 10.1177/0269881111414091, 21948935.
10. Keck PE, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997, 33:87-91.
11. Keck PE, McElroy SL, Strakowski SM, et al. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996, 57:147-151.
12. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006, 163:247-256. 10.1176/appi.ajp.163.2.247, 16449478.
13. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009, 166:476-488. 10.1176/appi.ajp.2008.08020189, 19289454.
14. National Institute of Health and Clinical Excellence (NICE) Clinical guideline 38: Bipolar disorder July 2006. Available at: http://www.nice.org.uk/nicemedia/live/10990/30193/30193.pdf. Accessed August 29, 2012, National Institute of Health and Clinical Excellence (NICE).
15. Goodwin M. Consensus group of the British association for psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British association for psychopharmacology. J Psychopharmacol 2009, 23:346-388. 10.1177/0269881109102919, 19329543.
16. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11:225-255. 10.1111/j.1399-5618.2009.00672.x, 19419382.
17. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004, 184:337-345. 10.1192/bjp.184.4.337, 15056579.
18. Collegium Internationale Psychiatriae Scalarum (CIPS) Internationale Skalen für Psychiatrie (4 Auflage) 1996, Göttingen: Beltz-Test GmbH, Collegium Internationale Psychiatriae Scalarum (CIPS).
19. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73:159-171. 10.1016/S0165-1781(97)00123-6, 9481807.
20. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for 2010 Available at: http://apps.who.int/classifications/apps/icd/icd10online. Accessed August 29 2012.
21. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183. 10.1017/S0033291700050182, 6133297.
22. Wilhelm S, Schacht A, Minarzyk A, et al. Preventing bipolar relapse: which factors are associated with different mood stabilizer therapy? Analysis of baseline data from a German observational study. Eur Psychiatry 2007, 22(Suppl):144. AEP 2007, Madrid.
23. Kessing LV, Søndergård L, Kvist K, Andersen PK. Adherence to lithium innaturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord 2007, 9:730-736. 10.1111/j.1399-5618.2007.00405.x, 17988363.